ISM012-042 是一种口服有效的选择性 PHD1 和 PHD2 抑制剂(IC50 值分别为 1.9 nM 和 2.5 nM),通过稳定肠道上皮细胞内的 HIF1α 蛋白,激活与粘液生成、紧密连接形成、抗炎介质产生和伤口愈合相关的基因转录程序,从根源上促进黏膜屏障修复并调节肠道免疫,可用于炎症性肠病的研究。
产品编号: MS-M59435 CAS No.: 2924181-80-4 分子式: C25H27N7O4 分子量: 489.53
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价

产品描述

ISM012-042 是一种口服有效的选择性 PHD1 和 PHD2 抑制剂(IC50 值分别为 1.9 nM 和 2.5 nM),通过稳定肠道上皮细胞内的 HIF1α 蛋白,激活与粘液生成、紧密连接形成、抗炎介质产生和伤口愈合相关的基因转录程序,从根源上促进黏膜屏障修复并调节肠道免疫,可用于炎症性肠病的研究。

生物实验数据

生物活性 ISM012-042 is an orally active and selective inhibitor of PHD1 and PHD2 with IC50 values of 1.9 nM and 2.5 nM, respectively, which stabilizes HIF1α protein in intestinal epithelial cells to activate gene transcription programs associated with mucus production, tight junction formation, anti-inflammatory mediator production, and wound healing, thereby promoting mucosal barrier repair at its root and modulating intestinal immunity, and can be used for research on inflammatory bowel disease.
体外研究
(In Vitro)

ISM012-042 (6 h) 可在 Caco-2 HIF1α-HiBit 细胞中稳定 HIF1α,其 EC50 值为 2.0 至 3.5 μM,且在不同细胞外铁浓度下仍可维持活性。
ISM012-042 (2.5 μM; 0-96 h) 可保护 Caco-2 细胞单层免受 DSS (MS-A45736) 诱导的肠屏障破坏。
ISM012-042 (1-10 μM; 24 h) 可呈剂量依赖性降低经 LPS 刺激的小鼠骨髓来源树突状细胞 (BMDCs) 中促炎因子 IL-12p35 和 TNF 的 mRNA 表达。
ISM012-042 (3 μM; 25 h) 可维持 ZO1 在 Caco-2 细胞间连接部位的定位,抵御 DSS 诱导的紧密连接破坏。

Real Time qPCR

Cell Line: Murine bone marrow-derived dendritic cells (BMDCs) stimulated with lipopolysaccharide (LPS)
Concentration: 1, 3, 10 μM
Incubation Time: 24 h (concurrent with LPS stimulation)
Result: Dose-dependently reduced IL-12p35 mRNA expression relative to LPS-stimulated vehicle controls.
Dose-dependently reduced TNF mRNA expression relative to LPS-stimulated vehicle controls.

Immunofluorescence

Cell Line: Caco-2 cells treated with DSS
Concentration: 3 μM
Incubation Time: 1 h pretreatment, then 24 h concurrent with DSS
Result: Retained ZO1 at cell-cell contacts, preventing DSS-induced tight-junction disruption.
体内研究
(In Vivo)

ISM012-042 (1-10 mg/kg;口服;每日一次;持续 6-9 天) 可通过恢复肠屏障功能、减轻肠道炎症,呈剂量依赖性缓解 TNBS 诱导的小鼠结肠炎。
ISM012-042 (1-10 mg/kg;口服;每日一次;持续 6-9 天) 可呈剂量依赖性地减轻 Oxazolone (MS-H07799) 诱导的小鼠结肠炎 (一种辅助性 T 细胞 2 型驱动疾病模型),其作用机制为降低肠道炎症、恢复肠屏障功能,且对 EPO 或 VEGF 水平无全身影响。

Animal Model: BALB/c (female, 8 weeks old, ~19-21 g body weight, TNBS-induced colitis)
Dosage: 1 mg/kg (prevention mode); 3 mg/kg (prevention mode; therapeutic mode); 10 mg/kg (prevention mode; therapeutic mode)
Administration: p.o.; daily; 9 days (prevention mode: day -1 to day 7); 6 days (therapeutic mode: day 2 to day 7)
Result: Reduced disease activity index (DAI) scores to levels comparable to 100 mg/kg mesalamine (3 and 10 mg/kg, prevention mode).
Reduced body weight loss, colon shortening, and colon weight (3 and 10 mg/kg, prevention mode).
Improved colonic histopathology scores (3 and 10 mg/kg, prevention mode).
Dose-dependently increased colon HIF1α staining intensity and mRNA expression of barrier-protective genes Tff3, Tjp1 and Nt5e (prevention mode).
Reduced plasma levels of proinflammatory cytokines IL-6 and TNF (prevention mode).
Reduced fecal lipocalin 2 (LCN2) and calprotectin levels (prevention mode).
Promoted weight gain and ameliorated disease severity within 48 hours (3 and 10 mg/kg, therapeutic mode).
Improved colonic gross pathology (3 and 10 mg/kg, therapeutic mode).
Reduced plasma fluorescein isothiocyanate (FITC)-dextran levels, indicating restored intestinal barrier function (3 and 10 mg/kg, therapeutic mode).
Reduced proportions of colonic lamina propria monocytes, neutrophils, and proinflammatory CD3+ T cell subsets (TNF+, IFNγ+, IL-17A+) relative to vehicle controls (3 and 10 mg/kg, therapeutic mode).
Animal Model: BALB/c (female, 8 weeks old, ~18-20 g body weight, oxazolone-induced colitis)
Dosage: 1 mg/kg (prevention mode); 3 mg/kg (prevention mode; therapeutic mode); 10 mg/kg (prevention mode; therapeutic mode)
Administration: p.o.; daily; 9 days (prevention mode: day -1 to day 7); 6 days (therapeutic mode: day 2 to day 7)
Result: Dose-dependently prevented body weight loss, improved DAI scores, improved colon density, and reduced fecal LCN2 levels (prevention mode).
Reduced colon tissue levels of proinflammatory chemokines (KC/GRO, MCP1, MIP1α, MIP2) and cytokines (IL-33, IL-5, IL-12p70, TNF) (prevention mode).
Reduced plasma IL-1β levels while leaving systemic EPO and VEGF levels unchanged (prevention mode).
Promoted disease remission, improved DAI scores, reduced plasma FITC-dextran levels (restored intestinal permeability), and normalized colon weight and length relative to vehicle controls (3 and 10 mg/kg, therapeutic mode).
性状 固体
颜色 White to off-white

化学信息

分子量 489.53
分子式 C25H27N7O4
CAS No. 2924181-80-4

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (51.07 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.0428 mL10.2139 mL20.4278 mL51.0694 mL
5 mM0.4086 mL2.0428 mL4.0856 mL10.2139 mL
10 mM0.2043 mL1.0214 mL2.0428 mL5.1069 mL
15 mM0.1362 mL0.6809 mL1.3619 mL3.4046 mL
20 mM0.1021 mL0.5107 mL1.0214 mL2.5535 mL
25 mM0.0817 mL0.4086 mL0.8171 mL2.0428 mL
30 mM0.0681 mL0.3405 mL0.6809 mL1.7023 mL
40 mM0.0511 mL0.2553 mL0.5107 mL1.2767 mL
50 mM0.0409 mL0.2043 mL0.4086 mL1.0214 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础